{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"27"},{"groupId":"OG001","value":"39"},{"groupId":"OG002","value":"23"},{"groupId":"OG003","value":"4"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"78"},{"groupId":"OG001","value":"57"},{"groupId":"OG002","value":"36"},{"groupId":"OG003","value":"20"}],"units":"Participants"}],"description":"ORR was defined as the percentage of participants with a confirmed Complete Response (CR) or Partial Response (PR) by investigator assessment as per RECIST v1 .1 criteria. Specifically, ORR = (number of subjects with a confirmed best overall response of CR or PR) divided by the total number of subjects in the corresponding analysis population.","groups":[{"description":"Participants who have relapsed or progressed after receiving at least one line of prior anti-cancer therapy for metastatic disease received dabrafenib 150 mg BID. It was continued until disease progression or death or unacceptable AEs or investigator discretion to discontinue or decision to crossover from monotherapy to combination therapy.","id":"OG000","title":"Cohort A (Dabrafenib Monotherapy)"},{"description":"Participants who had received 1-3 prior lines of systemic anti-cancer therapies for advanced stage/metastatic disease received Dabrafenib 150 mg BID and Trametinib 2 mg once daily (OD). Treatment continued until disease progression, death, or unacceptable AEs or investigator discretion to discontinue.","id":"OG001","title":"Cohort B - Double Combination (Dabrafenib+Trametinib) mBRAF V600E: DAB 150MG BID, TRA 2mG QD"},{"description":"Participants who had not received any prior systemic anti-cancer for metastatic disease therapies were given Dabrafenib 150 mg BID and Trametinib 2 mg OD. Treatment continued until disease progression, death, or unacceptable AEs or at investigator discretion to discontinue.","id":"OG002","title":"Cohort C - Double Combination (Dabrafenib+Trametinib) Naive mBRAF V600E: DAB 150MG BID, TRA 2mG QD"},{"description":"Crossover - Double Combination (Dabrafenib+Trametinib): Participants received Dabrafenib 150 mg BID in combination with Trametinib 2 mg once daily and continued treatment until disease progression, death, or unacceptable adverse event.","id":"OG003","title":"Crossover - Double Combination (Dabrafenib+Trametinib): DAB 150MG BID, TRA 2mG QD"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"All Treated Population (ATP).","reportingStatus":"POSTED","timeFrame":"From study treatment start date until first documented complete response or partial response, assessed up to approximately 50 months","title":"Overall Response Rate (ORR)","type":"PRIMARY","unitOfMeasure":"Participants"}